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C A N C E R
BAP1 regulates epigenetic switch from pluripotency 
to differentiation in developmental lineages giving rise 
to BAP1-mutant cancers
Jeffim N. Kuznetsov1*, Tristan H. Aguero2*, Dawn A. Owens1,2, Stefan Kurtenbach1, Matthew G. Field1, 
Michael A. Durante1, Daniel A. Rodriguez1, Mary Lou King2, J. William Harbour1†
The BAP1 tumor suppressor is mutated in many human cancers such as uveal melanoma, leading to poor patient 
outcome. It remains unclear how BAP1 functions in normal biology or how its loss promotes cancer progression. 
Here, we show that Bap1 is critical for commitment to ectoderm, mesoderm, and neural crest lineages during 
Xenopus laevis development. Bap1 loss causes transcriptional silencing and failure of H3K27ac to accumulate at 
promoters of key genes regulating pluripotency-to-commitment transition, similar to findings in uveal melanoma. 
The Bap1-deficient phenotype can be rescued with human BAP1, by pharmacologic inhibition of histone deacetylase 
(HDAC) activity or by specific knockdown of Hdac4. Similarly, BAP1-deficient uveal melanoma cells are preferen-
tially vulnerable to HDAC4 depletion. These findings show that Bap1 regulates lineage commitment through 
H3K27ac-mediated transcriptional activation, at least in part, by modulation of Hdac4, and they provide insights 
into how BAP1 loss promotes cancer progression.
INTRODUCTION
BAP1 [breast cancer type 1 (BRCA1)–associated protein 1] is emerg-
ing as an important tumor suppressor in human cancer (1), as it 
frequently sustains inactivating mutations in uveal melanoma, renal 
cell carcinoma, mesothelioma, and other malignancies (2–4). How-
ever, the role of BAP1 in normal and tumor biology remains unclear. 
BAP1 encodes a conserved nuclear-localizing ubiquitin C-terminal 
hydrolase that deubiquitinates multiple substrates, including histone 
H2A, host cell factor 1 (HCF1; also known as HCFC1), O-linked 
N-acetylglucosamine transferase, BRCA1, and the transcription factor 
Kruppel-like factor 5 (1, 5). Bap1 protein is found in nuclear com-
plexes containing HCF1, the Polycomb group (PcG) proteins ASXL1-3 
(“ASXLs”), the forkhead transcription factors FoxK1 and FoxK2 
(FOXK1-2), the lysine-specific demethylase 1B (KDM1B), and the 
transcription factor Yin Yang 1 (YY1) (1), suggesting a role for BAP1 in 
epigenetic regulation of gene expression. Early cell culture experiments 
suggested a role for BAP1 in cell cycle regulation (5–7), but in vivo 
studies have revealed a more complex biological role for BAP1 involving 
development and differentiation. In Drosophila, the BAP1 ortholog 
calypso is required for embryonic development and cooperates with Asx 
to protect transcriptionally active developmental genes against silencing 
by the Polycomb repressive complex 1 (PRC1) (8, 9). In mice, BAP1 
loss in the germ line is embryonic lethal (10), and BAP1 loss in the 
developing kidney causes differentiation failure and tumorigenesis 
(11). In human uveal melanoma and renal cell carcinoma, BAP1 
loss leads to a dedifferentiated stem-like phenotype associated with 
aggressive cancer behavior and poor patient outcome (2, 3). To gain new 
insights into the role of BAP1 in development and tumorigenesis, 
we investigated its role in vertebrate embryogenesis using Xenopus 
laevis as a model system.
BAP1 expression is restricted to neural crest progenitor 
lineages early in embryogenesis
The Xenopus Bap1 protein shares 92% similarity and 71% identity 
with human BAP1, compared to 85 and 66%, respectively, for zebrafish 
(fig. S1A). Amino acid identity exceeds 90% in conserved regions, 
such as the catalytic domain and the binding motifs for HCF1 and 
ASXLs (fig. S1B). Maternally derived bap1 mRNA is abundant in 
Xenopus oocytes, and embryonic bap1 transcription commences at 
the midblastula transition (fig. S1C). In contrast, Bap1 protein was 
not detected until the 32-cell stage (stage 6), with progressively in-
creasing protein levels thereafter (fig. S1D), suggesting a silencing 
period in which bap1 transcripts are translationally repressed. By 
the gastrulation stage, bap1 mRNA is expressed predominantly in 
ectoderm/mesoderm and becomes restricted to neural plate later, 
during early neurulation (fig. S2, A to C). By midneurula, bap1 
mRNA was detected in the midbrain region and the lateral and 
anterior neural folds, areas that give rise to neural crest cells and 
sensorial placodes, including the early eye field (fig. S2, D and E). 
Later in development, bap1 mRNA expression is restricted to migrat-
ing cranial neural crest cells, branchial arches, otic vesicle, and eye 
fields (fig. S2, F and G). A similar pattern was observed for Bap1 
protein expression (fig. S2, H to L).
Loss of Bap1 during Xenopus development produces 
a distinctive phenotype
To investigate the effects of Bap1 loss during development, we 
designed an antisense morpholino oligonucleotide that binds the 
5′ untranslated region (5′UTR) of bap1 (Bap1MO) and efficiently 
blocks translation of Bap1 protein (fig. S3, A and B, and data file S1). 
Injection of Bap1MO into one blastomere in two-cell–stage embryos 
interfered with blastopore closure, leading to a delay or arrest in 
gastrulation on the injected side, compared to the uninjected con-
trol side (Fig. 1, A and B). This early phenotype may explain why 
homozygous germline deletion of Bap1 in mice is associated with 
embryonic lethality (10). The same phenotype was observed, albeit 
at a lower frequency, using a different morpholino that only targets 
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Fig. 1. Loss of Bap1 during Xenopus development produces a distinctive phenotype. (A) Representative embryos analyzed at late gastrula (stage 12) following injection 
into one blastomere at the two-cell stage of escalating doses (7.5, 10, and 20 ng) of a morpholino targeting the 5′UTR of bap1 mRNA (Bap1MO) or a bap1 base pair mismatch 
control morpholino (Bap1MO-Ctrl). Below each bright-field image is a corresponding fluorescence image demonstrating fluorescein isothiocyanate as a lineage tracer for 
the injected side (green color). Depletion of Bap1 produces gastrulation failure, as evidenced by incomplete blastopore closure (arrows). Arrowheads indicate injected 
side. Panels show dorsal view, anterior down. (B) Summary of results of experiments described in (A), showing that depletion of Bap1 produces gastrulation failure ranging 
from mild (yellow) to severe (red) in a dose-dependent manner. (C) Representative embryos treated as above with 7.5 ng of Bap1MO, which eventually completed gastrula-
tion and developed axial foreshortening and bending (arrow) starting at early tail bud stages, compared to uninjected sibling embryos. Panels show lateral view, anterior 
left, except the lower right panel, which shows dorsal view, anterior down. (D) Representative embryos treated as above with 7.5 ng of Bap1MO, which eventually completed 
gastrulation and were evaluated at stage 37 or 45, showing microphthalmia or anophthalmia (black arrows) starting at late tail bud stages, and proliferation of morphologi-
cally immature melanoblasts with altered migration pattern (red arrows) starting at late tail bud and early tadpole stages. Panels show lateral view (except panels labeled 
dorsal view), anterior left. Arrowheads indicate the injected side. (E) Transverse sections through the head of a representative early–tadpole stage embryo stained with 
hematoxylin and eosin, following injection into one blastomere (D1.2) at the 16-cell stage with 7.5 ng of Bap1MO, showing disruption of eye development on the side 
injected with Bap1MO (right side, arrowhead), compared to normal eye development on the uninjected control side (left side). Dotted line indicates midline. (F) Normal 
histologic appearance of the eye at early–tadpole stage embryo [same orientation as (E)], with ocular structures indicated. RPE, retinal pigment epithelium. (G to I) Represent-
ative eyes at late tail bud/early–tadpole stage embryos showing mild (G), moderate (H), and severe (I) ocular malformation associated with injection of 7.5 ng of Bap1MO into 
blastomere D1.2 (which gives rise to retina, lens, and other eye structures) at the 16-cell stage. In severe cases, such as the example in (I), retinal tissue does not form, and the 
eye remains filled with yolk platelets (pink). (J) Whole-mount in situ hybridization (WISH) of indicated eye markers in embryos injected with 7.5 ng of Bap1MO and a lineage 
tracer into D1.2 at the 16-cell stage and analyzed at the indicated stages, showing aberrant development of ocular tissues in the absence of Bap1. Markers include ventx2 
(dorsal retina, unaffected), pax2 (ventral optic stalk), mitf and dct [retinal pigment epithelium and uveal melanocytes (UMCs)], rx1 (ciliary marginal zone and photoreceptor), 










Kuznetsov et al., Sci. Adv. 2019; 5 : eaax1738     18 September 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
3 of 11
the bap1 open reading frame, thereby causing less efficient knock-
down of Bap1 compared to the 5′UTR morpholino (fig. S3A, data file S1). 
In contrast, a base pair mismatch control morpholino (Bap1MO-Ctrl) 
that is unable to bind wild-type bap1 mRNA (fig. S3A and data file 
S1) caused no phenotypic abnormalities (Fig. 1, A and B), confirming 
the specificity of the morpholino-driven Bap1 depletion phenotype. 
About 75% of Bap1MO-injected embryos exhibited gastrulation 
abnormalities, yet ~60% eventually completed gastrulation and pro-
ceeded through development, where they demonstrated additional 
malformations, including axial foreshortening (Fig. 1C), microph-
thalmia or anophthalmia (Fig. 1, D to J), and proliferation of im-
mature melanoblasts with an altered migration pattern during late 
tail bud and early tadpole stages (Fig. 1D). To confirm that the eye 
phenotype is a direct effect of Bap1 loss, we knocked down Bap1 
specifically in cells destined to form the future eye field by injecting 
Bap1MO into blastomere D1.2—which gives rise to retina, lens, and 
other eye structures (12)—in 16-cell stage embryos. In the absence 
of Bap1, the dorsal eye structures appeared morphologically normal, 
but the medial and ventral eye structures failed to form properly 
(Fig. 1, E to I). Consistent with morphologic findings, the dorsal eye 
marker vent2 was unaffected by Bap1 loss, whereas medial and ventral 
eye markers were depleted or absent (Fig. 1J). The Bap1MO phenotype 
was rescued by coinjection of Bap1MO with either human BAP1 
mRNA (fig. S4, A to C) or a morpholino-resistant Xenopus bap1 
mRNA (bap1-MM) containing conservative nucleotide substitutions 
that abolish morpholino binding (fig. S3A).
Bap1 loss deregulates expression of pluripotency 
and lineage commitment genes
To identify embryonic lineages affected by Bap1 loss, we assessed 
spatial mRNA expression of key developmental genes using whole-
mount in situ hybridization (WISH). During gastrulation and early 
neurulation, Bap1-depleted embryos not only failed to silence the 
pluripotency factors vent1 and vent2 (orthologs of mammalian Nanog) 
and oct25 and oct91 (orthologs of mammalian Oct4) but also failed 
to switch on expression of lineage-specific factors, such as fzd7 (dorsal 
mesoderm and ectoderm), vegT, brachyury, and myoD (mesoderm), 
keratin1 (non-neural ectoderm), sox2 (neural ectoderm), rx1 (pre-
sumptive eye field), zic1 and msx1 (neural fold/prospective neural 
crest), and foxD3 and sox10 (neural crest) (Fig. 2). The expression of 
these molecular markers was restored to wild type by coinjection of 
human BAP1 mRNA or morpholino-resistant bap1 (fig. S4D). The 
pattern of transcriptomic disruption observed in Bap1-deficient 
embryos is evocative of our findings in human uveal melanoma, 
where BAP1 loss was associated with up-regulation of pluripotency 
markers and silencing of neural crest/melanocyte lineage markers 
(2). These findings validated the specificity of Bap1MO, demon-
strated the conserved function of Bap1 across vertebrate species, 
confirmed that Xenopus Bap1 is a bona fide ortholog of human 
BAP1, and indicated that Bap1 is required for normal development 
by promoting the transcriptional switch from pluripotency to commit-
ment in multiple lineages.
Bap1 function during development is dependent on its 
catalytic activity and interaction with Asxls
To explore how Bap1 regulates these transcriptional programs, we 
first asked whether it requires interaction with Asxls, which are among 
the most abundant Bap1-interacting proteins in Xenopus embryos 
(data file S2A) and human uveal melanoma cells, as well as other 
vertebrate cells (6, 10). The predominant family member expressed 
during Xenopus development is asxl1, and its pattern of mRNA ex-
pression closely parallels that of bap1 (fig. S5, A and B). To analyze 
Asxl1 function in vivo, we designed two specific morpholinos that 
target asxl1.S and asxl1.L, respectively, which were used together 
and referred to hereafter as Asxl1MO (data file S1). Asxl1 depletion 
resulted in morphogenetic defects identical to those observed in 
Bap1-deficient embryos (fig. S5C). Asxls interact with Bap1 through 
a highly conserved Asxl-binding motif (ABM) comprising amino acid 
residues 618 to 641 located in the Bap1 C-terminal region (fig. S1B) 
(13). This interaction promotes histone H2A deubiquitination by 
increasing the affinity of Bap1 for ubiquitinated Lys119 (8, 13, 14). We 
generated a complementary DNA (cDNA) expression construct 
encoding a Bap1 protein containing a four–amino acid deletion 
within the ABM (Bap1ABM) to abrogate Bap1-Asxl1 binding 
(fig. S3, C and D). In contrast to wild-type Bap1 and human BAP1, 
Bap1ABM failed to rescue the Bap1-deficient morphogenetic pheno-
type (fig. S5D). Similarly, a Bap1 mutant containing a single amino acid 
substitution at the conserved catalytic Cys91 residue (Bap1-C91W), 
corresponding to a human cancer–derived missense mutation that 
abrogates ubiquitin hydrolase activity (15), also failed to rescue the 
Bap1MO phenotype (fig. S3C and data not shown). Since most BAP1 
missense mutations in human tumors cluster around the ABM and 
catalytic domain (1, 2, 13), the functions of Bap1 in development seem 
to parallel those in tumor suppression.
Loss of Bap1 abrogates the assembly of H3K27ac at 
promoters of key genes regulating lineage commitment 
and differentiation
Bap1 and Asxls form the catalytic and regulatory subunits, re-
spectively, of the polycomb repressive deubiquitinase (PR-DUB) that 
deubiquitinates histone H2A at Lys119, thereby opposing the 
H2AK119 ubiquitin ligase activity of the PRC1 complex (8, 14) that, 
in turn, promotes the repressive PRC2-mediated trimethylation of 
H3K27 (16, 17). To explore in further detail the transcriptional and 
epigenetic programs disrupted by Bap1 loss, we performed RNA se-
quencing (RNA-seq) and chromatin immunoprecipitation followed 
by DNA sequencing (ChIP-seq) in late gastrula stage embryos (stage 
12), injected with either Bap1MO or control morpholino at one-cell 
stage (data file S2, B and C). Consistent with WISH experiments, 
RNA-seq shows that depletion of Bap1 abrogated the induction of 
genes regulating ectoderm, mesoderm, and neural crest commitment, 
including components of the Wnt and Hippo pathways (Fig. 3, A 
and B). As expected, depletion of Bap1 resulted in a global increase 
in H2AK119ub and H3K27me3 around transcription start sites across 
the genome (Fig. 3C). Unexpectedly, however, the histone mark that 
is most strongly associated with failed expression of lineage com-
mitment genes in Bap1-depleted embryos is H3K27ac (Fig. 3D), 
with promoters around many of these genes failing to assemble 
H3K27ac in the absence of Bap1 (Fig. 3E and data file S2D).
Pharmacologic inhibition of histone deacetylase activity 
rescues Bap1-deficient gastrulation phenotype
Since Bap1 orchestrates the assembly of H3K27ac at particular lineage 
commitment genes, we reasoned that the abnormalities resulting 
from Bap1 loss may be rescued, at least in part, by opposing histone 
deacetylase (HDAC) activity. Treatment of Bap1-depleted embryos 
starting at the 32-cell stage (stage 6) with the pan-HDAC inhibitor 
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allowing embryos to complete blastopore closure (fig. S6A). In contrast, 
no rescue was observed with pharmacologic inhibition of Ring1, the 
catalytic subunit of the PRC1 complex that ubiquitinates H2AK119, nor 
with depletion of the PRC1 core component Bmi1 (fig. S6C). Addition of 
a Bmi1-directed morpholino exacerbates the gastrulation defect caused 
by the Bap1-directed morpholino (data file S1 and data not shown), 
suggesting that PRC1 and the Bap1-containing PR-DUB complex do 
not function in a purely antagonistic relationship, similar to findings in 
Drosophila (8). Similarly, no rescue was observed with a pharmacological 
inhibition of the PRC2 catalytic subunit enhancer of zeste homolog 2 
(Ezh2), which catalyzes trimethylation of H3K27 (fig. S6C).
Hdac4 is a key mediator of the Bap1-deficient phenotype
Since SAHA inhibits numerous HDACs, we questioned whether 
there may be a specific HDAC that is up-regulated by Bap1 loss and 
mediates the Bap1-deficient phenotype. By comparing RNA-seq data 
from our embryo experiments to the publicly available human uveal 
melanoma RNA-seq data from The Cancer Genome Atlas (TCGA) 
Fig. 2. Bap1 loss deregulates expression of pluripotency and lineage commitment genes. (A to P) Representative embryos injected with 7.5 ng of the Bap1MO 
morpholino into one blastomere at the two-cell stage (arrowheads indicate injected side) and then fixed and analyzed for mRNA expression of the indicated developmental 
genes by WISH at the specified stages (gastrula, stage 12; midneurula, stages 14 to 17; early tail bud, stage 24). Bap1-depleted embryos fail to silence pluripotency factors 
such as vent1/2 (orthologs of mammalian Nanog) and oct25 (ortholog of mammalian Oct4) (A to C) and fail to activate lineage commitment factors such as fzd7 (dorsal 
mesoderm and ectoderm), vegT and bra (axial mesoderm), myoD (muscle), keratin1 (non-neural ectoderm), sox2 (neural ectoderm), rx1 (early eye field), zic1 and msx1 
(neural fold/prospective neural crest), and foxD3 and sox10 (neural crest) (D to N). Bap1 loss results in a failure of neural crest cell migration in sox10-expressing cells 
compared to the uninjected control (O and P). Panels show the dorsal-caudal view (A, B, and D to F), the dorsal view (C and G to N), or the lateral view (O and P), anterior 
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(18), we observed that HDAC4 is the only HDAC that is significantly 
up-regulated [false discovery rate (FDR) < 0.001] by BAP1 loss 
in both datasets (fig. S7A). Therefore, we designed two specific 
morpholinos that target hdac4.S and hdac4.L, respectively, which were 
used together and referred to hereafter as Hdac4MO (fig. S3A and 
data file S1). Concomitant depletion of Bap1 and Hdac4 in whole 
embryos using Bap1MO and Hdac4MO rescues the Bap1-deficient 
phenotype, as evidenced by restoration of normal morphologic 
development (Fig. 4, A and B); transcriptional activation of lineage 
commitment genes such as sox2, bra, msx1, and fzd7 (Fig. 4C); and 
Fig. 3. Loss of Bap1 abrogates the assembly of H3K27ac at promoters of key genes regulating lineage commitment and differentiation. (A) Heat map demon-
strating the top 1000 most differentially expressed genes by RNA-seq between embryos at one-cell stage with 15 ng of either Bap1MO or Bap1MO-Ctrl and collected at 
late gastrulation (stage 12), when morphologic effects of Bap1 loss are first evident. (B) Gene set enrichment analysis (GSEA) plots demonstrating the most highly significant 
pathways represented by the differentially expressed genes associated with Bap1 loss. FDR, false discovery rate. (C) Heat maps of ChIP-seq data demonstrating global 
genomic occupancy of the indicated histone marks across all annotated genes in embryos treated as above with either Bap1MO or Bap1MO-Ctrl. TSS, transcription start 
site. (D) Violin plots summarizing ChIP-seq data restricted to differentially expressed genes. (E) ChIP-seq and RNA-seq tracks of representative lineage commitment genes 
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accumulation of H3K27ac at the promoters of lineage commitment 
genes (Fig. 4D). Together, these findings implicate Hdac4 as an im-
portant mediator of Bap1 function by controlling the timely assembly 
of H3K27ac at genes regulating induction of multiple embryonic 
lineages.
Hdac4 acts independently of the Smrt/Ncor1-Hdac3 complex
Since HDAC4 has been shown to interact with the SMRT/NCoR-
HDAC3 repressor complex (19), we wondered whether the Smrt/
Ncor1 complex plays a role in the Bap1-deficient phenotype. To 
address this possibility, we first compared the changes in gene ex-
pression associated with depletion of Bap1 to those associated with 
depletion of both Bap1 and Hdac4. However, differentially expressed 
genes were not enriched for a curated list of SMRT/NCoR gene targets 
(JEPSEN_SMRT_TARGETS) using gene set enrichment analysis 
(GSEA) (data not shown). Next, we investigated whether the Bap1- 
deficient phenotype could be rescued using an Hdac3-directed 
morpholino (Hdac3MO). In contrast to Hdac4, depletion of Hdac3 
had no effect on Bap1-deficient embryos (fig. S7, B and C). These 
findings suggest that regulation of Hdac4 by Bap1 is not mediated 
through Smrt/Ncor1-Hdac3, at least during the stages of develop-
ment under investigation here.
Antagonistic effect of HDAC4 and BAP1 in human uveal 
melanocytic cells
Hdac4 was not found among Bap1-interacting proteins in stage 12 frog 
embryos analyzed by mass spectrometry (data file S2A), suggesting 
that Bap1 and Hdac4 may interact functionally rather than through 
direct physical interaction. Consequently, we hypothesized that Bap1 
may regulate Hdac4 by modulating its nuclear-cytoplasmic shuttling, 
an important mechanism for regulating its activity (20). Hdac4 is 
largely restricted to the cytoplasm in BAP1 wild-type uveal melanoma 
Fig. 4. Hdac4 is a key mediator of the Bap1-deficient phenotype. (A) Representative embryos injected at the one-cell stage with 7.5 ng of Bap1MO with or without 
16 ng of a morpholino directed against Hdac4 (Hdac4MO) and analyzed at midneurula stage (stage 15, dorsal view, anterior to left) and early tail bud stage (stage 26, 
lateral view, anterior to left). (B) Summary of results at stages 15 and 26, showing substantial rescue of the Bap1-deficient phenotype with Hdac4MO. (C) Representative 
embryos treated as above and analyzed by WISH, demonstrating that failed induction of the indicated developmental genes in Bap1-deficient embryos is rescued by 
Hdac4MO. Caudal view, dorsal up. (D) ChIP–quantitative polymerase chain reaction (qPCR) for indicated gene promoters following ChIP for H3K27ac, confirming that 
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cells and in normal human uveal melanocytes (UMCs), whereas it 
localized to the nucleus in BAP1-mutant uveal melanoma cells and in 
UMCs in which a BAP1 mutation was introduced using CRISPR-Cas9 
(fig. S7D). Thus, Bap1 appears to inhibit the epigenetic function of 
Hdac4, at least in part, by restricting its localization to the nucleus. 
Moreover, short hairpin RNA (shRNA)–mediated depletion of 
HDAC4 in BAP1-mutant uveal melanoma cells significantly im-
paired cell proliferation (fig. S8). Future work will be needed to 
elucidate the mechanism by which Bap1 carries out this function.
DISCUSSION
Disruption of Bap1 during development results in abnormalities 
largely affecting ectoderm, mesoderm, and neural crest, which may 
help to explain the spectrum of cancers associated with BAP1 muta-
tions, which are mostly derived from those lineages (1). At the or-
ganismal level, BAP1 primarily appears to regulate cell identity and 
differentiation, rather than cell cycle and proliferation, which may 
explain why BAP1 mutations typically are not initiating events but, 
rather, later events associated with cancer progression (3, 21). Germ-
line BAP1 mutations usually do not result in tumor formation un-
less accompanied by an initiating mutation, such as a Gq mutation 
in uveal melanoma or a BRAF mutation in cutaneous melanoma 
(21, 22). This phenomenon may explain why families with germline 
BAP1 mutations display reduced penetrance for any specific cancer 
type (23). While BAP1 can exert diverse effects through multiple 
interacting partners (1), our findings indicate that a critical function 
of Bap1 in development is to prevent deacetylation of H3K27 at 
genes regulating lineage commitment in a manner dependent on 
its deubiquitinase activity. Consistently, H3K27 deacetylation and 
H2AK119 ubiquitination represent two early chromatin alterations 
that enforce gene silencing during embryonic development (24). 
When Bap1 is lost in susceptible cell types, H3K27ac fails to accu-
mulate at key promoters, at least in part, because of unrestrained 
Hdac4 activity, which may explain why BAP1 loss sensitizes uveal 
melanoma and mesothelioma cells to treatment with HDAC inhibi-
tors (25, 26). These findings provide novel insights into the role of 
BAP1 in development and cancer, and they suggest HDAC inhibitors 
as potential therapeutic agents for treating BAP1-mutant cancers.
MATERIALS AND METHODS
Embryo manipulation
To obtain X. laevis embryos, female frogs were induced to ovulate 
by injecting 500 to 700 U of human chorionic gonadotropin sub-
cutaneously, directly above the dorsal lymph sacs. After injection, 
females were maintained in the dark at 18°C overnight. After females 
began ovulating the following morning, one male was euthanized by 
placing it in 0.1% tricaine solution buffered with sodium bicarbonate 
for 30 min. Both testes were dissected and placed into a 35-mm dish 
containing 1.5 ml of 1× Mark’s modified ringer (MMR) solution 
[0.1 M NaCl, 2 mM KCl, 1 mM MgSO4, 2 mM CaCl2, and 5 mM 
Hepes (pH 7.8)]. Eggs were gently squeezed from females into 10-cm 
plates. Sperm were released to fertilize the eggs by mincing a small 
portion of the testes in a few drops of 1× MMR placed beside the 
eggs followed by gentle mixing of eggs and sperm together. After 
10 min at room temperature (RT), the fertilized eggs were flooded 
with 0.1× MMR solution (pH 7.4). Embryos were dejellied using 
2% l-cysteine solution (pH 7.8) for 2 min. Embryos were washed thrice 
with 0.1× MMR solution and placed in 0.1× MMR. At the desired 
developmental stage, embryos were injected with a Nanoject II Auto- 
Nanoliter Injector (Drummond Scientific Inc.). Injected embryos 
were maintained in 4% Ficoll/0.1% MMR solution at 18°C until they 
reached stage 9 and then transferred to 0.1× MMR buffer.
Histological analysis, WISH, and immunohistochemistry
X. laevis embryos were injected with morpholinos and/or mRNAs 
into one blastomere at the 1-, 2-, or 16-cell stage and collected at 
different stages; staging was according to Nieuwkoop and Faber (27). 
For histologic analysis, embryos were embedded into Paraplast, and 
12-m sections were cut on a rotary microtome and stained with 
hematoxylin and eosin. Immunohistochemistry for Bap1 was per-
formed as previously described (28) using an antibody raised against 
human BAP1 (H300; Santa Cruz Biotechnology, Santa Cruz, CA) at 
a 1:100 dilution. Embryos were incubated with the primary antibody 
for 24 hours and then incubated with alkaline phosphatase (AP)–
conjugated secondary antibody (ab6729, Abcam, Cambridge, MA). 
Color was developed using a combination of nitro blue tetrazolium 
(NBT) chloride  and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) 
(Promega, Madison, WI). WISH was performed as described (29). 
Embryos were fixed in 4% MEMFA [100 mM MOPS (pH 7.4), 2 mM 
EGTA, and 1 mM MgSO4, and 3.7% (v/v) formaldehyde] 1 hour at 
RT, dehydrated with 100% methanol in three 10-min washes, and 
either kept at −20°C in methanol or rehydrated through a methanol 
wash series {75, 50, and 25% in PTw [phosphate-buffered saline (PBS) 
buffer and Tween 20]} for 5 min each step, followed by a 5-min PTw 
wash. Embryos were rinsed for 5 min, prehybridized with hybrid-
ization buffer at 65°C for 5 to 6 hours, and then hybridized over-
night in hybridization buffer containing the appropriate amount of 
antisense probe at 65°C. Next, embryos were sequentially washed in 
50% formamide/2× SSC and 0.1% Tween 20 (10 min/60°C), 25% 
formamide/2× SSC and 0.1% Tween 20 (10 min/60°C), 12.5% 
formamide/2× SSC and 0.1% Tween 20 (10 min/60°C), 2× SSC and 
0.1% Tween 20 (10 min/60°C), and 0.2× SSC and 0.1% Tween 20 
(30 min/60°C). After three 5-min washes with PTw and two 5-min 
washes with maleic acid buffer (MAB), embryos were placed in 
MAB/2% Boehringer Blocking Reagent (BMB) blocking reagent 
(Roche) for 2 hours and then incubated in MAB/2% BMB containing 
1:3000 diluted anti-digoxigenin/AP (Roche, Basel, Switzerland) over-
night. After incubation, embryos were washed six times with MAB 
for 30 min each and twice with fresh AP buffer for 5 min, transferred to 
a precooled color reaction solution (AP buffer containing NBT chloride 
and BCIP), and incubated at RT in the dark until sufficient staining 
was reached. The staining reaction was stopped by replacing the 
staining solution with methanol, twice for 5 min. Embryos were left 
in a third methanol wash for 40 min at 62°C and then washed three 
to five times with water for rehydration. To bleach pigments, embryos 
were treated with 2% H2O2 in 1× PBS (stocks: 30% H2O2 and PBS 
20×) under fluorescent light for 4 to 6 hours, washed several times with 
water, and stored in 4% formaldehyde in 1× PBS at 4°C. In all experi-
ments in which embryos were injected past the one-cell stage, fluo-
rescein isothiocyanate was coinjected to mark the injected side.
Morpholinos and DNA constructs
Morpholino antisense oligonucleotides were designed and synthesized 
against X. laevis bap1, asxl, and hdac4, targeting both homologs, from 
the long and short chromosomes (Gene Tools LLC). Morpholino 
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Doses of 5 to 15 ng per embryo were microinjected as mentioned 
above. Plasmids containing cDNA clones that were used to generate 
WISH RNA probes were obtained from previously described sources 
(data file S1). The following constructs were purchased from GE 
Dharmacon (Lafayette, CO): asxl1 (ID446414), bap1 (ID493568), and 
fzd7 (ID378787). Mutations were introduced to Xenopus bap1 and 
asxl1 cDNA using a Q5 site-directed mutagenesis kit (New England 
Biolabs, Ipswich, MA).
Mass spectrometry
FLAG-tagged Xenopus bap1 mRNA was synthesized from Not I–
linearized pCS2+ plasmids using mMESSAGE mMACHINE SP6 
transcription kit (Thermo Fisher Scientific, Waltham, MA). Embryos 
were injected at the one-cell stage with 0.5 ng of the synthetic mRNA 
and maintained at 22°C until they reached stage 12. Then, ~250 
injected embryos were collected and lysed in 2.5 ml of mammalian 
cell PE LB buffer (G-Biosciences, St. Louis, MO) containing a com-
plete protease inhibitor cocktail (Roche, Indianapolis, IN) by pass-
ing embryos through a 21-gauge needle ~20 times, placed on ice 
for 30 min, and then centrifuged at 12,000g for 10 min to obtain 
clear lysates. An equal number of uninjected sibling embryos 
were processed in an identical fashion, and then 1× FLAG peptide 
(Sigma-Adrich, St. Louis, MO) was added to the clear lysate to the 
final concentration of 10 ng/ml to be used as a control. Both FLAG-
Bap1 and FLAG-containing control lysates were precleared by coin-
cubation with magnetic protein G beads (Thermo Fisher Scientific, 
Waltham, MA) and mouse immunoglobulin G (2 g/ml) at 4°C for 
2 hours. Final coimmunoprecipitation was performed overnight at 
4°C using FLAG-M2 mouse antibody, followed by a 10-min wash 
with coimmunoprecipitation buffer. The magnetic beads containing 
coimmunoprecipitated complexes were sent for further processing 
and analysis to the Proteomics and Metabolomics Shared Resource 
at The Wistar Institute (Philadelphia, PA). Mass spectrometry find-
ings were filtered in the following manner. Any protein with a 
label-free quantification (LFQ) intensity greater in the control than 
the FLAG-Bap1 sample was discarded. In addition, all proteins 
were removed where the control LFQ intensity was >1% of the 
corresponding FLAG-Bap1 LFQ intensity. Furthermore, proteins 
were required to have at least an LFQ intensity of 5,000,000 and two 
unique peptide reads. Last, results were filtered for known mass 
spectrometry contaminants of FLAG-tagged experiments using the 
CRAPome (www.nature.com/articles/nmeth.2557).
In vitro translation
In vitro translation was carried out using wheat germ extracts accord-
ing to the manufacturer’s instructions (Promega, Madison, WI). A 
total of 1.0 g of capped-mRNA and different amounts of morpholinos 
were used per reaction. Protein expression was then analyzed by 
Western blot.
SAHA rescue experiments
Two-cell stage embryos were injected into one blastomere with 10 ng 
of Bap1MO and maintained in 4% Ficoll/1× MMR solution at 22°C 
until maturing to stage 6. SAHA was dissolved in 100% dimethyl 
sulfoxide (DMSO) to make a 1 mM stock solution and kept at −20°C. 
SAHA was added to medium containing the embryos to a final con-
centration of 20 M. Control sibling embryos were treated with an 
equal volume of DMSO. Upon reaching stage 10, embryos were 
transferred to 0.1 MMR solution supplemented with fresh SAHA 
every 4 hours. Embryos were collected and fixed at different stages 
for morphological and molecular analysis.
ChIP-seq and ChIP–quantitative polymerase chain reaction
ChIP-seq and ChIP–quantitative polymerase chain reaction (qPCR) 
were performed on 500 and 100 stage 12 embryos, respectively, ac-
cording to a protocol from the Cold Spring Harbor Laboratory (30), 
with 35 min of cross-linking. Sodium N-lauroylsacrosine in buffer 
E3 was replaced by 0.1% SDS, as suggested by the authors to increase 
specificity for certain antibody types. Chromatin was sonicated to 
an average fragment size of 200 base pairs (bp) with a Diagenode 
Bioruptor Pico before ChIP. A total of 5 g of antibody was used 
for each ChIP, with the exception of H2AubK119, where 2 g 
was used. The following antibodies were used to perform ChIP: 
H2AK199ub (Cell Signaling Technology, D27C4, no. 8240), H3K27me3 
(Cell Signaling Technology, C36B11, 9733BF), H3K27AC (Active 
Motif, no. 39133), and H3K4me3 (Active Motif, no. 39915). Libraries 
were prepared using the NEBNext Ultra kit and sequenced on the 
Illumina NextSeq 500 (1 × 75 bp). ChIP-seq data were marked for 
duplicates using Picard (v1.128) and filtered for mapping quality us-
ing SAMtools (v1.2). Normalization of tracks was conducted using 
THOR, with binning set to 10/5 (31). Plotting of the average ChIP-
seq signals was performed using a custom script. Heat maps were 
generated with deeptools (32), and kmeans clustering selected to 
compute the matrices. Quantification of ChIP-seq data for specific 
regions was done using bedtools (33). Genes that did not have 
National Center for Biotechnology Information (NCBI) annotations 
were identified via a custom-built script, which performed automated 
alignment using BLASTN online alignment tool against the NCBI 
genome database. The unidentified genes were assigned a name based 
on the alignment score ≥200. ChIP-qPCR primer sequences were 
deposited in ChIPprimersDB (34) and are listed in data file S1.
RNA sequencing
Embryos were injected at the one-cell stage with 15 ng of Bap1MO- 
Ctrl or Bap1MO and maintained at 22°C until they reached stage 12. 
RNA was isolated with TRIzol/chloroform, and yolk and pigment 
were further removed from samples using RNeasy MinElute Cleanup 
Kit (QIAGEN), according to the manufacturer’s protocol. Libraries 
were prepared using the NEBNext Ultra kit and sequenced on the 
Illumina NextSeq 500 (1 × 75 bp). Next generation sequencing quality 
was assessed using FastQC (v0.11.3). Reads were trimmed (if re-
quired) and aligned to the X. laevis 9.1 genome (www.xenbase.org/) 
using STAR (v2.5.2a) (35). Read counts of RNA-seq data were ob-
tained using HTSeq (36) and analyzed for differential expression 
using EdgeR (37) with batch correction for paired experimental data. 
X. laevis gene names were changed to the names of human homo-
logs to allow GSEA (38), which was conducted with recommended 
parameters and annotated gene sets obtained from the Molecular 
Signatures Database (39). To compare the differential expression of 
HDACs with respect to BAP1 status in Xenopus embryos and human 
uveal melanoma samples, we analyzed RNA-seq data from 80 pri-
mary human UMs generated by the TCGA (http://cancergenome.
nih.gov/) (21).
Cell culture
This study was approved by the Institutional Review Board, and writ-
ten informed consent was obtained from the patients. A BAP1 wild-
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melanoma cell line (UMM061) were generated from patient-derived 
xenografts (PDXs) generated from patients undergoing enucleation. 
PDXs were expanded in the intrascapular fat pad of NOD.Cg- 
Prkdcscid Il2rgtm1Wjl/SzJ JAX immunodeficient (NSG) mice for 
up to 3 months. The tissue was digested with collagenase IV for 
3 hours at 37°C, dissected into a single-cell suspension by pipetting, 
and cultured in 5% partial pressure of oxygen (pO2) in the UMM 
media containing Dulbecco’s modified essential medium (DMEM)/
F12 with 5% heat-inactivated fetal bovine serum (HI-FBS), B-27 
minus vitamin A (Life Technologies), 1% penicillin-streptomycin, 
2 mM Glutamax, basic fibroblast growth factor (bFGF) (10 ng/ml) 
(PeproTech), recombinant stem cell factor (rSCF) (10 ng/ml) 
(PeproTech), and epidermal growth factor (20 ng/ml) (PeproTech). 
Cell culture surface was coated with 0.1% porcine gelatin (Millipore 
Sigma) before plating. PDX-derived BAP1-mutant UM cell line MP38 
and BAP1 wild-type UM cell line MP41 were provided by S. Roman- 
Roman (40) and maintained in 5% pO2 in DMEM/F12 with 10% 
HI-FBS, 1% penicillin-streptomycin, 2 mM Glutamax, and 0.5% 
insulin-transferrin-selenium (Thermo Fisher Scientific). A cell line 
was generated from a normal UMC sample derived from unaffected 
normal intraocular uveal tissue in a patient undergoing enucleation. 
The uveal tissue was digested with collagenase IV for 3 hours at 37°C, 
dissected into a single-cell suspension by pipetting, and cultured in 
5% pO2 in the UMC media containing Ham’s F12 with 10% HI-FBS, 
1% penicillin-streptomycin, 2 mM Glutamax, 100 M 3-isobutyl- 1-
methylxanthine, and 10 ng/ml of each: bFGF (PeproTech), rSCF 
(PeproTech), and cholera toxin (Sigma-Aldrich). UMCs were enriched 
relative to other cell types by addition of G418 (100 g/ml) (Thermo 
Fisher Scientific) to the media for the first 5 days in culture. UMCs 
were then immortalized by retroviral expression of human TERT 
(Addgene plasmid no. 1773), followed by hygromycin selection. 
UMCs with knockout of BAP1 were created by clonally isolating 
UMCs stably transduced with lentiviral particles encoding spCAS9 
(Addgene plasmid no. 50661) and guide RNA against BAP1 (Addgene 
plasmid no. 64114) directing the CRISPR-mediated deletion of the 
first exon of the BAP1 gene. Immunofluorescence microscopy was 
performed on UM and UMC cells using Santa Cruz Biotechnology 
antibodies against HDAC4 (sc-46672) and BAP1 (sc-28236). shRNA 
CGACAGGCCTCGTGTATGATT and AAATTACGGTCCAGGC-
TAATT sequences targeting human HDAC4 cDNA (shHDAC4) 
were individually cloned into a pLH-spsgRNA2 vector (Addgene 
plasmid no. 64114) and stably integrated into UM cells via lentiviral 
transduction and selection with hygromycin B (50 g/ml). Nonspecific 
shRNA sequence AACAGCCACAACGTCTATATC (shSCR) was 
used as control. Equal amount of shSCR- or shHDAC4-expressing 
cells was plated into 12-well plate, and after 2 weeks, the cells were 
stained using 0.5% crystal violet and 6% glutaraldehyde solution 
and counted using ImageJ.
Real-time reverse transcription PCR
Total RNA from three embryos was extracted using TRIzol (Invitro-
gen), and cDNA synthesis was carried out using random hexamer 
priming and the StrataScript Reverse Transcriptase. Quantitative 
reverse transcription PCR was performed on the 7900HT Fast 
Real-Time PCR TaqMan System (Applied Biosystems) using the 
Brilliant SYBR Green qPCR Master Mix (Stratagene). Measurements 
were performed in triplicates and normalized to the expression levels 
of eukaryotic translation elongation factor 1  (ef1a). Bars indicate 
SE. The primer sequences are described in data file S1.
Ethical use of animals
The animal protocols used in this work were evaluated and approved 
by the Institutional Animal Care and Use Committee of the University 
of Miami (no. 12-276). All activities were performed in compliance 
with federal state and institutional regulations. The University 
was granted full accreditation by the Association for Assessment 
and Accreditation of Laboratory Animal Care, International in 
February 2005 and received its current reaccreditation in 14 March 2019. 
In addition, University of Miami is licensed by the U.S. Department 
of Agriculture and has filed a Letter of Assurance with the Office 
of Laboratory Animal Welfare, U.S. Department of Health and 
Human Services.
Statistical analysis
For GSEA, significance was assessed using FDR (38). Two-tailed 
t test was applied unless otherwise specified.
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Fig. S1. X. laevis and human Bap1 proteins show extensive sequence homology. (A) 
Similarity and identity comparisons between Xenopus laevis (Xl), Xenopus tropicalis (Xt), 
human (H), and zebrafish (Zf) Bap1 proteins. (B) Sequence alignment of human and Xenopus 
laevis Bap1 proteins. (C) Expression of bap1 mRNA by RT-qPCR at the indicated stages during 
Xenopus laevis early development (vertical yellow bars indicate standard error). (D) Detection of 
Bap1 protein by western blot at the indicated stages during Xenopus laevis early development. A 
total of 50 µg of protein was loaded into each lane, except for stage 50, in which 20 µg of protein 







Fig. S2. Anatomic distribution of Xenopus bap1 mRNA and Bap1 protein expression 
during early development. (A) By whole-mount in situ hybridization, bap1 mRNA (blue color) 
is located diffusely in early mesoderm and ectoderm at gastrulation. (B-C) bap1 mRNA (arrows) 
becomes restricted to the early developing neural plate at stages 13-14. (D-E) Bap1 mRNA 
(arrows) is circumscribed at the lateral and anterior neural plate borders, including prospective 
neural crest, non-neural ectoderm, mid-brain, and sensorial placode, at stage 15. (F) During early 
tailbud stages, bap1 mRNA is located in migrating cranial neural crest cells and optic vesicle 
(arrows). (G) In late tailbud stage, bap1 mRNA is localized to branchial arches and otic vesicle 
(arrows). Panels show posterior view, dorsal at top (A), dorsal view, anterior side left (B-D), 
anterior at bottom, dorsal side up (E), and lateral view, anterior left (F,G). Dotted lines indicate 
midline; note symmetry of bap1 expression. (H-J) By immunohistochemistry, Bap1 protein 
(arrows) is detected at the neural plate border during neurulation stages. (K) During early tailbud 
stages, Bap1 protein is localized to the eye field (dashed white oval), migrating cranial neural 
crest (arrowhead), and brain (arrow). (L) During later tailbud stages, Bap1 protein is mostly 
localized to eye field (dashed white oval), brachial arches (arrowhead), and otic vesicle (arrow). 
Panels show dorsal view, anterior side left (A-C), and lateral view, anterior side left (K,L). 




Fig. S3. Bap1 morpholinos and expression constructs. (A) Schematic representations of Bap1, 
Hdac3, Hdac4, and control morpholinos (red bars) and their binding sites within their targeted 
mRNAs (blue bars). Base-pair mismatches are indicated in black. (B) Validation of morpholino 
efficiency using in vitro wheat germ extracts for protein translation after incubating bap1 mRNA 
with either control or increasing amounts of Bap1 morpholino (5’-UTR). (C) Schematic 
representations of recombinant proteins. Bap1ΔABM includes a deletion within the Asxl binding 
motif (ABM). Bap1-C91W contains a point mutation in the ubiquitin hydrolase catalytic 
cysteine. (D) Co-immunoprecipitation followed by western blot validating that the Bap1ΔABM 
mutant protein does not bind efficiently to Asxl1. Anti-FLAG (for Bap1) and Anti-V5 (for 









Fig. S4. Developmental abnormalities in Bap1-deficient embryos are rescued by exogenous 
human BAP1. (A) Representative embryos analyzed at late tailbud stage following injection 
into one blastomere at the two-cell stage of 7.5 ng Bap1MO or 7.5 ng Bap1MO plus 1 ng human 
BAP1 mRNA, which is not recognized by Bap1MO. Fluorescein isothiocyanate (FITC) is a 
lineage tracer for the injected side (green). Microphthalmia eye defect is rescued by human 
BAP1 mRNA. Panels show lateral view, anterior left. (B) Human BAP1 mRNA rescues the 
failure of embryo development, associated with Bap1 loss, in a dose-dependent manner. 
Embryos were injected with 7.5 ng Bap1MO plus human BAP1 mRNA and analyzed at early 
tailbud stages (n=300 embryos from three different females, >90% with phenotype) (C) Visual 
representation of embryos summarized in B, showing the human BAP1 mRNA rescue effect 
ranging from indistinguishable from wild-type (blue), to mild mesodermal foreshortening 
(yellow) to severe spina bifida (red). Panels show dorsal view, anterior left. (D) Representative 
embryos at gastrula and neurula stages treated as above and analyzed by whole mount in situ 
hybridization, demonstrating that failed expression of the indicated developmental genes in 
Bap1-deficient embryos was rescued by human BAP1 mRNA. Panels show posterior view, 






Fig. S5. Loss of Asxl1 phenocopy loss of Bap1 during Xenopus development. (A) RNA-seq 
global expression profiling of bap1, asxl1, asxl2 and asxl3 during Xenopus development 
(Xenbase.org), showing strongest correlation between bap1 and asxl1 expression. L and S 
indicate transcripts from long and short chromosomes, respectively. (B) Anatomic distribution of 
asxl1 mRNA expression at the indicated stages of Xenopus laevis development analyzed by 
whole mount in situ hybridization, showing strong similarity to bap1 expression pattern. Panels 
show lateral view, anterior left. (C) Representative embryos analyzed at the indicated stages 
following injection into one blastomere at the two-cell stage of 10 ng of Asxl1MO. Asxl1-
deficiency phenocopied axial foreshortening, microphthalmia and abnormal melanocyte 
phenotype observed with Bap1-deficiency (see Fig. 1). Panels show lateral view, anterior left, 
except right panel showing dorsal view, anterior side down (arrow indicates injected side). (D) 
Summary of rescue experiments using either morpholino-resistant Xenopus bap1 (bap1-MM) or 
bap1 containing a mutation at the Asxl binding motif (bap1ABM) to rescue the Bap1-deficient 
phenotype caused by Bap1MO (n=300 embryos from three different females, >85% with 
phenotype, analyzed at late tailbud stages). In contrast to bap1-MM, co-injection with 
bap1ABM provided no rescue, indicating that Bap1 requires interaction with Asxls for its 






Fig. S6. Pharmacologic rescue of Bap1-deficient phenotype. (A) Treatment of embryos with 
pan-histone deacetylase inhibitor SAHA at mid-neurula (stage 14-16) following injection into 
one blastomere at two-cell embryo stages with 7.5 ng Bap1MO and incubated from blastula to 
neurula stages (stage 9 to 15) with DMSO alone (left 2 columns) or with 20 M SAHA in 
DMSO (right 2 columns). Fluorescence images are shown to the right of each corresponding 
color image to demonstrate FITC as a tracer for the injected side (green). (B) Summary of 
experiments (n=300 embryos from three different females, >90% with phenotype), showing 
substantial rescue of Bap1-deficient phenotype with SAHA treatment and lack of toxicity in 
control Bap1MO-Ctrl injected embryos. (C) Summary of results (n=835 embryos from three 
different females, >90% with phenotype) using the Ring1 inhibitor (PRC1 complex) PRP4165 
and the Ezh2 inhibitor (PRC2 complex) GSK126, neither of which demonstrated rescue of the 
Bap1-deficient phenotype. Embryos were analyzed at mid-neurula (stage 14-16) following 
injection into one blastomere of two-cell embryos with 7.5 ng Bap1MO and incubated either 
with 20 M PRT4164 or 25 M GSK126 from blastula to early neurula stages (stage 9 to 13). 
Scale bar: 250 μm.  
 
 
Fig. S7. Hdac4 is a key mediator of Bap1-deficient phonotype and acts independently of 
Hdac3 during development. (A) Comparison of RNA-seq data from Xenopus laevis embryos 
and 80 human uveal melanoma samples from TCGA to identify histone deacetylases that are 
differentially expressed in association with BAP1 loss. (B) Representative embryos injected at 
the 1-cell stage with 15 ng of Bap1MO with or without 8 ng of a morpholino directed against 
Hdac3 (Hdac3MO), analyzed at mid-neurula stage (stage 15, dorsal view, anterior to left) and 
early tailbud stage (stage 26, lateral view, anterior to left). Scale bar: 250 μm. (C) Quantification 
of results depicted in B, showing no rescue of the Bap1-deficient phenotype by Hdac3MO 
(n=200 embryos from 2 females, >90% with phenotype). (D) Immunofluorescence imaging 
using antibodies against HDAC4 and BAP1 on normal human uveal melanocytes (UMC) that are 
wild-type for BAP1 (WT) or engineered to express a truncated inactive BAP1 protein using 
CRISPR/Cas9 (MUT). Primary uveal melanoma cells with wild-type BAP1 (UMM055 and 
MM66) or mutationally inactivated for BAP1 (UMM061 and MP38) were also examined. Scale 
bar: 50 μm.  
 
Fig. S8. Inhibition of HDAC4 significantly impairs proliferation of uveal melanoma cells in 
a BAP1-dependent manner. (A) Uveal melanoma cell lines with wild-type BAP1 (UMM055, 
MP41, and MM66) or with mutant BAP1 (UMM061, MP38, and MP46) were engineered to 
express shHDAC4 or control scrambled shSCR and plated at equal numbers (2x10
3
/well) and 
cultured for 2 weeks, after which they were stained with crystal violet and imaged under 20X 
magnification. BAP1-wildtype cells and control BAP1-mutant cells demonstrated typical 
morphology and growth, whereas BAP1-mutant cells expressing shHDAC4 demonstrated 
senescence phenotype and increased cell death. (B) To quantitate these findings, viable cells 
were counted using ImageJ. Each experiment was performed in triplicate. P values were 
determined by two-tailed t-test. *P<0.001, **P<0.05; n.s., not significant.
Supplemental Data Legends 
 
Data file S1. Oligonucleotides and plasmids used in this study. 
 
Data file S2. Proteomic, transcriptomic, and epigenomic analyses. (A) Mass spectrometry of 
Bap1 interacting proteins in Xenopus laevis stage 12 embryos. (B) RNA-seq data from Xenopus 
laevis stage 12 embryos analyzed for differentially expressed genes in wild-type and Bap1-
knockdown embryos. (C) Quantification of ChIP-seq signals for H3K27ac, H3K27me3, 
H3K4me3 and H2AK119ub around transcription start sites ± 2 kb. (D) Subset of genes with 
decrease in H3K27ac signal >40% and corresponding decrease in RNA-seq gene expression 
logFC < -0.6 in Bap1-knockdown stage 12 embryos compared to embryos injected with CtrlMO.   
 
 
 
 
 
 
 
 
